# Phase I/II Study of Neoadjuvant Chemoradiotherapy With S-1/ Oxaliplatin in Patients With Gastric Cancer: Randomized Phase II Study of S-1/RT vs. S-1/Oxaliplatin/RT

> **NCT01106066** · PHASE1,PHASE2 · TERMINATED · sponsor: **Samsung Medical Center** · enrollment: 30 (actual)

## Conditions studied

- Phase I: To Determine the Maximum Tolerated Dose (MTD)
- Phase II: To Assess the Pathologic CR Rate and Feasibility Following Neoadjuvant Chemoradiation Therapy With S1/Oxaliplatin

## Interventions

- **DRUG:** Oxaliplatin, S-1, radiotherapy

## Key facts

- **NCT ID:** NCT01106066
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Difficulties in recruiting patients
- **Last updated:** 2013-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01106066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01106066, "Phase I/II Study of Neoadjuvant Chemoradiotherapy With S-1/ Oxaliplatin in Patients With Gastric Cancer: Randomized Phase II Study of S-1/RT vs. S-1/Oxaliplatin/RT". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01106066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*